Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial
• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, En...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Clarke, Robert [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives - Nciri, A. ELSEVIER, 2022, The European menopause journal, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:80 ; year:2015 ; number:4 ; pages:426-431 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.maturitas.2015.01.013 |
|---|
| Katalog-ID: |
ELV023695935 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV023695935 | ||
| 003 | DE-627 | ||
| 005 | 20230625141621.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.maturitas.2015.01.013 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015013000024.pica |
| 035 | |a (DE-627)ELV023695935 | ||
| 035 | |a (ELSEVIER)S0378-5122(15)00030-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 |a 150 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 150 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.61 |2 bkl | ||
| 100 | 1 | |a Clarke, Robert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
| 264 | 1 | |c 2015transfer abstract | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. | ||
| 520 | |a • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. | ||
| 650 | 7 | |a Vitamin D supplementation trial |2 Elsevier | |
| 650 | 7 | |a Parathyroid hormone |2 Elsevier | |
| 650 | 7 | |a 25-Hydroxyvitamin D |2 Elsevier | |
| 700 | 1 | |a Newman, Connie |4 oth | |
| 700 | 1 | |a Tomson, Joseph |4 oth | |
| 700 | 1 | |a Hin, Harold |4 oth | |
| 700 | 1 | |a Kurien, Rijo |4 oth | |
| 700 | 1 | |a Cox, Jolyon |4 oth | |
| 700 | 1 | |a Lay, Michael |4 oth | |
| 700 | 1 | |a Sayer, Jenny |4 oth | |
| 700 | 1 | |a Hill, Michael |4 oth | |
| 700 | 1 | |a Emberson, Jonathan |4 oth | |
| 700 | 1 | |a Armitage, Jane |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Nciri, A. ELSEVIER |t Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives |d 2022 |d The European menopause journal |g Amsterdam [u.a.] |w (DE-627)ELV008932956 |
| 773 | 1 | 8 | |g volume:80 |g year:2015 |g number:4 |g pages:426-431 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.maturitas.2015.01.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.61 |j Innere Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 80 |j 2015 |e 4 |h 426-431 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
r c rc |
|---|---|
| matchkey_str |
clarkerobertnewmanconnietomsonjosephhinh:2015----:siainfhotmmoefiaidodsaervninnlepolrtoaeeinnbsl |
| hierarchy_sort_str |
2015transfer abstract |
| bklnumber |
44.61 |
| publishDate |
2015 |
| allfields |
10.1016/j.maturitas.2015.01.013 doi GBVA2015013000024.pica (DE-627)ELV023695935 (ELSEVIER)S0378-5122(15)00030-4 DE-627 ger DE-627 rakwb eng 610 150 610 DE-600 150 DE-600 610 VZ 44.61 bkl Clarke, Robert verfasserin aut Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D Elsevier Newman, Connie oth Tomson, Joseph oth Hin, Harold oth Kurien, Rijo oth Cox, Jolyon oth Lay, Michael oth Sayer, Jenny oth Hill, Michael oth Emberson, Jonathan oth Armitage, Jane oth Enthalten in Elsevier Science Nciri, A. ELSEVIER Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives 2022 The European menopause journal Amsterdam [u.a.] (DE-627)ELV008932956 volume:80 year:2015 number:4 pages:426-431 extent:6 https://doi.org/10.1016/j.maturitas.2015.01.013 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 80 2015 4 426-431 6 045F 610 |
| spelling |
10.1016/j.maturitas.2015.01.013 doi GBVA2015013000024.pica (DE-627)ELV023695935 (ELSEVIER)S0378-5122(15)00030-4 DE-627 ger DE-627 rakwb eng 610 150 610 DE-600 150 DE-600 610 VZ 44.61 bkl Clarke, Robert verfasserin aut Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D Elsevier Newman, Connie oth Tomson, Joseph oth Hin, Harold oth Kurien, Rijo oth Cox, Jolyon oth Lay, Michael oth Sayer, Jenny oth Hill, Michael oth Emberson, Jonathan oth Armitage, Jane oth Enthalten in Elsevier Science Nciri, A. ELSEVIER Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives 2022 The European menopause journal Amsterdam [u.a.] (DE-627)ELV008932956 volume:80 year:2015 number:4 pages:426-431 extent:6 https://doi.org/10.1016/j.maturitas.2015.01.013 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 80 2015 4 426-431 6 045F 610 |
| allfields_unstemmed |
10.1016/j.maturitas.2015.01.013 doi GBVA2015013000024.pica (DE-627)ELV023695935 (ELSEVIER)S0378-5122(15)00030-4 DE-627 ger DE-627 rakwb eng 610 150 610 DE-600 150 DE-600 610 VZ 44.61 bkl Clarke, Robert verfasserin aut Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D Elsevier Newman, Connie oth Tomson, Joseph oth Hin, Harold oth Kurien, Rijo oth Cox, Jolyon oth Lay, Michael oth Sayer, Jenny oth Hill, Michael oth Emberson, Jonathan oth Armitage, Jane oth Enthalten in Elsevier Science Nciri, A. ELSEVIER Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives 2022 The European menopause journal Amsterdam [u.a.] (DE-627)ELV008932956 volume:80 year:2015 number:4 pages:426-431 extent:6 https://doi.org/10.1016/j.maturitas.2015.01.013 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 80 2015 4 426-431 6 045F 610 |
| allfieldsGer |
10.1016/j.maturitas.2015.01.013 doi GBVA2015013000024.pica (DE-627)ELV023695935 (ELSEVIER)S0378-5122(15)00030-4 DE-627 ger DE-627 rakwb eng 610 150 610 DE-600 150 DE-600 610 VZ 44.61 bkl Clarke, Robert verfasserin aut Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D Elsevier Newman, Connie oth Tomson, Joseph oth Hin, Harold oth Kurien, Rijo oth Cox, Jolyon oth Lay, Michael oth Sayer, Jenny oth Hill, Michael oth Emberson, Jonathan oth Armitage, Jane oth Enthalten in Elsevier Science Nciri, A. ELSEVIER Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives 2022 The European menopause journal Amsterdam [u.a.] (DE-627)ELV008932956 volume:80 year:2015 number:4 pages:426-431 extent:6 https://doi.org/10.1016/j.maturitas.2015.01.013 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 80 2015 4 426-431 6 045F 610 |
| allfieldsSound |
10.1016/j.maturitas.2015.01.013 doi GBVA2015013000024.pica (DE-627)ELV023695935 (ELSEVIER)S0378-5122(15)00030-4 DE-627 ger DE-627 rakwb eng 610 150 610 DE-600 150 DE-600 610 VZ 44.61 bkl Clarke, Robert verfasserin aut Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. • The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D Elsevier Newman, Connie oth Tomson, Joseph oth Hin, Harold oth Kurien, Rijo oth Cox, Jolyon oth Lay, Michael oth Sayer, Jenny oth Hill, Michael oth Emberson, Jonathan oth Armitage, Jane oth Enthalten in Elsevier Science Nciri, A. ELSEVIER Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives 2022 The European menopause journal Amsterdam [u.a.] (DE-627)ELV008932956 volume:80 year:2015 number:4 pages:426-431 extent:6 https://doi.org/10.1016/j.maturitas.2015.01.013 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 80 2015 4 426-431 6 045F 610 |
| language |
English |
| source |
Enthalten in Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives Amsterdam [u.a.] volume:80 year:2015 number:4 pages:426-431 extent:6 |
| sourceStr |
Enthalten in Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives Amsterdam [u.a.] volume:80 year:2015 number:4 pages:426-431 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Innere Medizin |
| institution |
findex.gbv.de |
| topic_facet |
Vitamin D supplementation trial Parathyroid hormone 25-Hydroxyvitamin D |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives |
| authorswithroles_txt_mv |
Clarke, Robert @@aut@@ Newman, Connie @@oth@@ Tomson, Joseph @@oth@@ Hin, Harold @@oth@@ Kurien, Rijo @@oth@@ Cox, Jolyon @@oth@@ Lay, Michael @@oth@@ Sayer, Jenny @@oth@@ Hill, Michael @@oth@@ Emberson, Jonathan @@oth@@ Armitage, Jane @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV008932956 |
| dewey-sort |
3610 |
| id |
ELV023695935 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023695935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625141621.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.maturitas.2015.01.013</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015013000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023695935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5122(15)00030-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="a">150</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Clarke, Robert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vitamin D supplementation trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Parathyroid hormone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">25-Hydroxyvitamin D</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Newman, Connie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomson, Joseph</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hin, Harold</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kurien, Rijo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cox, Jolyon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lay, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sayer, Jenny</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hill, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emberson, Jonathan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Armitage, Jane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Nciri, A. ELSEVIER</subfield><subfield code="t">Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives</subfield><subfield code="d">2022</subfield><subfield code="d">The European menopause journal</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV008932956</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:80</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:426-431</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.maturitas.2015.01.013</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">80</subfield><subfield code="j">2015</subfield><subfield code="e">4</subfield><subfield code="h">426-431</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Clarke, Robert |
| spellingShingle |
Clarke, Robert ddc 610 ddc 150 bkl 44.61 Elsevier Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
| authorStr |
Clarke, Robert |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008932956 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 150 - Psychology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 150 610 DE-600 150 DE-600 610 VZ 44.61 bkl Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D Elsevier |
| topic |
ddc 610 ddc 150 bkl 44.61 Elsevier Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D |
| topic_unstemmed |
ddc 610 ddc 150 bkl 44.61 Elsevier Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D |
| topic_browse |
ddc 610 ddc 150 bkl 44.61 Elsevier Vitamin D supplementation trial Elsevier Parathyroid hormone Elsevier 25-Hydroxyvitamin D |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c n cn j t jt h h hh r k rk j c jc m l ml j s js m h mh j e je j a ja |
| hierarchy_parent_title |
Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives |
| hierarchy_parent_id |
ELV008932956 |
| dewey-tens |
610 - Medicine & health 150 - Psychology |
| hierarchy_top_title |
Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008932956 |
| title |
Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
| ctrlnum |
(DE-627)ELV023695935 (ELSEVIER)S0378-5122(15)00030-4 |
| title_full |
Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
| author_sort |
Clarke, Robert |
| journal |
Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives |
| journalStr |
Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 100 - Philosophy & psychology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
426 |
| author_browse |
Clarke, Robert |
| container_volume |
80 |
| physical |
6 |
| class |
610 150 610 DE-600 150 DE-600 610 VZ 44.61 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Clarke, Robert |
| doi_str_mv |
10.1016/j.maturitas.2015.01.013 |
| dewey-full |
610 150 |
| title_sort |
estimation of the optimum dose of vitamin d for disease prevention in older people: rationale, design and baseline characteristics of the best-d trial |
| title_auth |
Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
| abstract |
• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. |
| abstractGer |
• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. |
| abstract_unstemmed |
• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
4 |
| title_short |
Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial |
| url |
https://doi.org/10.1016/j.maturitas.2015.01.013 |
| remote_bool |
true |
| author2 |
Newman, Connie Tomson, Joseph Hin, Harold Kurien, Rijo Cox, Jolyon Lay, Michael Sayer, Jenny Hill, Michael Emberson, Jonathan Armitage, Jane |
| author2Str |
Newman, Connie Tomson, Joseph Hin, Harold Kurien, Rijo Cox, Jolyon Lay, Michael Sayer, Jenny Hill, Michael Emberson, Jonathan Armitage, Jane |
| ppnlink |
ELV008932956 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.maturitas.2015.01.013 |
| up_date |
2024-07-06T19:31:00.428Z |
| _version_ |
1803859274423599104 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023695935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625141621.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.maturitas.2015.01.013</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015013000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023695935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5122(15)00030-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="a">150</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Clarke, Robert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100μg or 50μg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England. • The primary analyses will compare 12-month mean plasma concentrations of 25(OH)D as well as the proportion of participants with a 12-month concentration >90nmol/L between participants allocated 100μg and participants allocated 50μg daily. Secondary analyses will compare the two active doses (both separately and when combined) with placebo. • Additional end-points include biochemical assessments of safety, blood pressure, arterial stiffness, falls, fractures, heel and wrist bone density, grip strength and physical performance and echocardiographic assessments of cardiac function in a random sample of participants. • The results of this trial will help determine the optimum dose of vitamin D to test in a larger trial investigating whether vitamin D supplementation can reduce the risk of fractures, cardiovascular disease or cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vitamin D supplementation trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Parathyroid hormone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">25-Hydroxyvitamin D</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Newman, Connie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomson, Joseph</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hin, Harold</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kurien, Rijo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cox, Jolyon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lay, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sayer, Jenny</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hill, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Emberson, Jonathan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Armitage, Jane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Nciri, A. ELSEVIER</subfield><subfield code="t">Les lymphomes du système digestif chez le sujet âgé : particularités cliniques et évolutives</subfield><subfield code="d">2022</subfield><subfield code="d">The European menopause journal</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV008932956</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:80</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:426-431</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.maturitas.2015.01.013</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">80</subfield><subfield code="j">2015</subfield><subfield code="e">4</subfield><subfield code="h">426-431</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399482 |